Venus Remedies Limited (NSE:VENUSREM)
India
· Delayed Price · Currency is INR 460.00
+1.05 (0.23%)
Jun 30, 2025, 11:30 AM IST
Venus Remedies Revenue
In the fiscal year ending March 31, 2025, Venus Remedies had annual revenue of 6.48B INR with 7.72% growth. Venus Remedies had revenue of 1.95B in the quarter ending March 31, 2025, a decrease of -0.10%.
Revenue
6.48B
Revenue Growth
+7.72%
P/S Ratio
0.94
Revenue / Employee
5.46M
Employees
1,187
Market Cap
6.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.48B | 464.40M | 7.72% |
| Mar 31, 2024 | 6.01B | 459.40M | 8.27% |
| Mar 31, 2023 | 5.56B | -446.71M | -7.44% |
| Mar 31, 2022 | 6.00B | 520.57M | 9.50% |
| Mar 31, 2021 | 5.48B | 2.07B | 60.90% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
Venus Remedies News
- 5 weeks ago - Venus Remedies renews GMP certification from Ukraine’s SMDC for Baddi facility - Business Upturn
- 2 months ago - Venus Remedies shares jump 11% after US FDA grants QIDP status to novel antibiotic VRP-034 - Business Upturn
- 2 months ago - Venus Remedies gets US FDA grants QIDP status to novel polymyxin B formulation VRP-034 - Business Upturn
- 4 months ago - Venus Remedies secures exclusive rights for MET-X clinical development in India - Business Upturn
- 5 months ago - Venus Remedies shares surge 10% after EU GMP Certification renewal - Business Upturn
- 5 months ago - Venus Remedies successfully renews EU GMP certification, reinforcing its European market presence - Business Upturn
- 6 months ago - Venus Remedies stock jumps 4% after receiving GMP certification for Antibiotic facility - Business Upturn
- 7 months ago - Venus Remedies shares surge 6% on Pemetrexed marketing authorization in Philippines - Business Upturn